Assessment of Light Therapy in Insomnia Disorder

ConditionInsomnia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-60
SponsorUniversity Hospital, Strasbourg, France

About this trial

Sleep disorders represent a major public health issue and the leader in these disorders is insomnia with 10 to 15% of subjects in the general population reporting symptoms of insomnia with a daytime impact. In addition to being very common, insomnia leads to an increase in morbidity and mortality and weighs on healthcare systems worldwide. Despite this public health context, insomnia is underdiagnosed and rarely treated. Hypnotics have proven efficacy but with a risk of dependence and pharmacotolerance which appears within a few weeks. Cognitive behavioral therapy (CBT) has a good level of evidence and is now a benchmark treatment for the management of insomnia. Unfortunately, not all patients adhere to or respond to these procedures, which cannot be implemented for many of them either. There is therefore a need to identify other alternative therapeutic strategies, and we believe that exposure to light is a promising treatment.

In this perspective, it seems interesting to assess the effect of the propensity to fall asleep with an exposure to light therapy in patients suffering from insomnia.

In order to be in optimal ecological conditions, we want to use a portable light therapy device which allows easy, acceptable and ambulatory exposure.

If the lighttherapy is confirmed in insomnia under ecological conditions, this would make it possible to propose a new non-drug treatment, easy to access and on a large scale

Eligibility criteria

Qualifiers

Patient aged 30 to 60 years

Insomnia disorders (ICSD-3) with sleep latency >30min - 3 times a week

Patient able to understand the objectives and risks associated with the research and to give informed dated and signed consent

Patient affiliated to a social health insurance scheme

Disqualifiers

- Shift work in the year preceding inclusion

Trans meridian travel (> 2 time zones) in the month preceding inclusion

Patient in exclusion period determined by a previous or ongoing study

Impossibility of giving the patient informed information (emergency patient, difficulty understanding the patient)

Trial design

Treatments tested in this trial

  • Placebo with light therapy glasses
  • light therapy with light therapy glasses

Treatment groups

66 Participants
are divided into 2 treatment groups